Moderate

Essential thrombocythaemia (ET; primary/essential thrombocytosis)

Myeloproliferative neoplasm · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Clonal MPN with sustained platelet count >450 x10^9/L (often >600-1000), driven by JAK2, CALR or MPL mutations. Risk is both thrombosis and (with extreme counts) bleeding from acquired von Willebrand syndrome. Exclude reactive thrombocytosis first. ED role: risk-stratify, start aspirin in most, treat thrombosis, refer.

Red flags

  • Acute thrombosis (stroke, MI, DVT/PE, splanchnic vein)
  • Microvascular: erythromelalgia, visual/neuro transient symptoms
  • Bleeding with platelet count >1000-1500 (acquired von Willebrand syndrome)
  • Progressive splenomegaly / cytopenias (transformation to myelofibrosis)

Assessment

Differential diagnosis

  • Reactive/secondary thrombocytosis (infection, inflammation, iron deficiency, post-splenectomy, malignancy, bleeding)
  • Other MPN (PV, early myelofibrosis, CML)
  • Myelodysplastic/myeloproliferative overlap (e.g. MDS/MPN-RS-T)

Investigations

  • FBC + film (large platelets, confirm sustained count on repeat)
  • JAK2 V617F; if negative CALR and MPL mutation analysis
  • CRP/ESR, ferritin (exclude reactive causes/iron deficiency)
  • BCR-ABL1 to exclude CML
  • Von Willebrand screen (ristocetin cofactor) if platelets very high (>1000-1500) and bleeding
  • Bone marrow biopsy (megakaryocyte morphology) per haematology

Management

  • Confirm true sustained thrombocytosis and exclude reactive causes (treat the cause if reactive)
  • Assess thrombotic/haemorrhagic risk (age >60, prior thrombosis, JAK2 positive, cardiovascular risk, platelet >1500)
  • Start low-dose aspirin for most (vasomotor symptoms, JAK2-positive, CV risk) - but HOLD if acquired vWS/active bleeding until corrected
  • Treat any acute thrombosis per standard pathway
  • High-risk (age >60 or prior thrombosis): start cytoreduction (hydroxycarbamide first-line)
  • Extreme thrombocytosis with bleeding: check/treat acquired von Willebrand (avoid aspirin; cytoreduce urgently)
  • Manage cardiovascular risk factors

Drugs & doses

Aspirin 75-100 mg PO once daily (most patients; avoid if acquired vWS/bleeding)
Hydroxycarbamide (hydroxyurea) 15-20 mg/kg/day PO, titrate to platelets <400 x10^9/L (first-line high-risk) [verify local dose]
Anagrelide 0.5 mg PO twice daily, titrate (platelet-specific; caution cardiac, headache) [verify local dose]
Interferon alfa / peginterferon (younger patients, pregnancy) [verify local dose]
Plateletpheresis - reserved for acute life-threatening thrombosis/bleeding with extreme counts [verify local dose]

Disposition

Acute thrombosis/bleeding -> admit with haematology. Otherwise outpatient haematology referral for confirmation and risk-adapted therapy.

Complications & pitfalls

  • Arterial/venous thrombosis
  • Haemorrhage from acquired von Willebrand syndrome
  • Transformation to myelofibrosis or AML (less common than PV)
  • Pregnancy loss

Exam pearls

  • Platelets >1000-1500 can cause BLEEDING not clotting via acquired vWS - do not reflexively give aspirin; check ristocetin cofactor
  • Always exclude reactive thrombocytosis (iron deficiency, infection, malignancy) before labelling ET
  • CALR-mutated ET has lower thrombotic risk than JAK2-mutated
  • Erythromelalgia responds dramatically to aspirin

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.